At the beginning of the meeting, Doris, the financial representative, introduced the attending management, including the chairman, executive director, chief executive officer, chief operating officer, chief financial officer and company secretary. Subsequently, the chairman launched a performance profile, focusing on the Chinese and Western performance of the owner's medical group.

The company has shown solid growth in the first half of 2026, facing global challenges, achieving annual revenue growth of 18% to $99 million and gross profit margin of 68.5. Through the implementation of diversification and localization strategies, new products have performed well in the Japanese market, partnerships with manufacturers have been strengthened, and the establishment of direct sales networks has enhanced market opportunities. The Company is committed to rewarding its shareholders, and after considering its capital requirements, it has resolved to pay a dividend of HK $8 cents per share, and looking ahead, it will continue to optimize operational efficiency and market expansion.

In the first half of the year, the group's revenue increased by 18% year-on-year, gross profit margin remained at 68.5, and sales and distribution expenses increased by 20%. On the market side, the performance of major markets such as Mainland China, the United States and India was balanced. The financial position is sound, with total assets of about $0.46 billion and liabilities of about $40 million. The Group continued to expand its sales channels, increased investment in market activities and maintained a near-cash position with 93 days of accounts receivable turnover.

The report details the revenue growth in the first half of 2026 in a number of global markets, with particular emphasis on the significant improvement in the direct sales model, especially in Malaysia, Taiwan, Japan, mainland China and the United States. Growth in Malaysia Road was particularly prominent, with the Taiwan market driving new product sales through direct sales transformation. The Japanese market has achieved significant revenue growth due to the launch of new products, the Chinese mainland market has steadily increased its revenue with policy support, and the US market has achieved moderate revenue growth through a single trading strategy. Overall, the increase in the proportion of direct sales and the introduction of new products are the key factors driving revenue growth in each market.

The company continues to implement a rich product portfolio strategy, strong environmental protection departments and innovative product recommendations to promote long-term sustainable growth. In the Japanese market, the company is accelerating the product registration process and plans to complete the listing of multiple products by 2026. At the same time, to promote the global layout of the core products. In addition, the Japanese market is expected to be commercialized in 2030.

The Group has built a diversified product portfolio through mergers and acquisitions and cooperation, successfully promoted its core products in the European market, focused on the European direct sales network, increased product prices and gross profit margins, continued to develop and upgrade products, deepened cooperation with third parties, and expected significant growth in future performance.

Through diversified business development models, including ODM, OEM, equity investment and capital operation, the Group aims to integrate diversified products into the global sales system, enhance production capacity space, promote intelligent production upgrading, and strengthen supply chain stability planning to ensure that future production needs of new products are met. Management is confident in the Group's future prospects and has paid an interim dividend for the first time, reflecting its commitment to shareholder value.

The Group announced its first dividend, demonstrating financial soundness and long-term confidence, and plans to use $0.224 billion in cash through expanded production, strategic acquisitions and stable returns. Management actively evaluates the European market and considers increasing direct sales areas to maintain high growth, while exploring complementary opportunities for products and platforms.

Discussed the reasons for the slowdown in U.S. market earnings, including production, sales and economic environment impact, and asked about revenue growth after mergers and acquisitions, foreign exchange, etc., the company's expected revenue growth targets for mergers and acquisitions, as well as the domestic product market performance and the contribution of products with kylie.

Discussed the potential opportunities in the Taiwan market in the first half of 2026, as well as the company's current sales expense pressure and growth expectations in the next 2-3 years. Mentioned the expected impact of M & A activities on revenue, as well as strategies to enhance the sales platform through self-built markets and collaborative models. The development potential of new products and the importance of cooperation with peers are emphasized, while the company's incremental and preliminary work progress in the European market is pointed out.

The dialogue revolved around the Group's R & D investment, revenue ratio, and OEM business growth. Management said it will maintain investment in research and development, while planning to expand the OEM business, emphasizing the Group's focus on core business and its own product line development, the future OEM business is expected to become one of the focus.

Discussed revenue and gross margin forecasts for the next six months to next year, the impact of overseas direct sales team expansion on sales expense ratios, and the possible increase in administrative expenses due to policy changes, emphasizing the importance of improving core operating margins.

The meeting discussed the revenue growth in the Chinese market, which is around 408, and highlighted the impact on DCD after product optimization expenses, as well as the struggling sales in Macau. Management said it looked forward to future acceptance of the Chinese market by increasing product value and optimizing assets, while mentioning strategies to diversify risk and increase pipeline interest rates.